Login / Register The Most Trusted Name in Medical Education

Pathology

Elsevier's complimentary continuing medical education courses in pathology are targeted to healthcare providers in lab medicine.

1 BANNER

Management of Patients with Relapsed/Refractory Multiple Myeloma: Elsevier CME Independent Conference Highlights from EBMT and EHA 2018

Format: Conference Reporter

*This webcast is not endorsed by the conference organizer. The Elsevier Office of Continuing Medical Education is an independent medical education company that provides clinical updates, analysis, and expert perspectives through conference-coverage educational programs.

In this CME-accredited webcast, three experts discuss the clinical implications of some of the latest important research on relapsed/refractory multiple myeloma (RRMM). The roundtable discussion covers new data presented at the 2018 annual meetings of the European Hematology Association (EHA) and the European Society for Blood and Marrow Transplantation (EBMT). The topics discussed include: unmet needs in the treatment of RRMM; new data on treatment strategies (including the roles of proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies); and emerging treatments, such as chimeric antigen receptor (CAR) T-cell therapies.

Credits: 1.0 AMA PRA Category 1 Credit™
910750 116 x 140

ESMO 2017: A Therapeutic Update on the Management of Patients with Metastatic Renal Cell Carcinoma

Format: Medical Meeting Reporter

This webcast on metastatic renal cell carcinoma (mRCC) is based on a roundtable discussion among three key opinion leaders in the field. The experts will present updates on the management of mRCC and summarize and discuss the latest clinical trial data presented during the ESMO 2017 Congress, held in Madrid, Spain, on September 8–12, 2017. Advances in the use of targeted therapies such as VEGFR inhibitors, novel immunotherapies, and combination therapies including PD-1/PD-L1 and CTLA4 targeting agents will be examined. The experts will address the question of how novel treatment options could be included in individualized treatment plans when approved, to optimize treatment selection and outcomes for patients with mRCC.

Take Course »

 

Credits: 1.0 AMA PRA Category 1 Credit™
910752 116 x 140

ESMO 2017: A Therapeutic Update on the Management of Patients with Advanced Hepatocellular Carcinoma

Format: Medical Meeting Reporter

This webcast on hepatocellular carcinoma (HCC) is based on a presentation by an expert, who provides an overview of the advances in the management of HCC and summarizes and discusses the latest data presented during the European Society for Medical Oncology (ESMO) Annual Meeting 2017, held on September 8-12 in Madrid, Spain. Results of clinical trials of targeted therapies that have been evaluated in first-line and second-line setting in advanced HCC and their possible effect on treatment guidelines will be examined. Additionally, the potential role of biomarkers as prognostic factors of response to targeted therapies, particularly in clinical practice, will also be discussed. The expert will also discuss the most promising new agents in advanced clinical trials in HCC and how they might impact the treatment landscape in HCC.

Take Course »

 

Credits: 1.0 AMA PRA Category 1 Credit™
Elsevier SITC ASCO 2018 01 Web 116x140 webcast

The IO Quiz Show: Biomarkers for Immunotherapy

Format: Webcast

This webcast was recorded at a live event at ASCO SITC 2018. During this event, three leading experts challenged participants with quiz questions, which formed a basis for in-depth discussions supported by slide presentations. Participants were able to test and expand their knowledge on the increasingly important role of biomarkers in immuno-oncology. The experts examined the tumor microenvironment and addressed the evidence base for, and the future potential of, current and emerging biomarkers in guiding treatment decisions and in predicting the response to immuno-oncology therapeutics. Participants also learned about the role and importance of next-generation sequencing for the evaluation of novel immune biomarkers and for daily clinical practice.

Take Course »

Credits: 1.0 AMA PRA Category 1 Credits™
Thumbnail 116x140 LearningCenter v2

Progress in Pancreatic Cancer

Format: Resource Center

Welcome to the Progress in Pancreatic Cancer Learning Center. This Learning Center is a freely accessible, educational platform for healthcare providers who treat patients with pancreatic cancer

Our goal is to ensure that you – the practicing clinician – have access to the most accurate, up-to-date information for the treatment of patients with pancreatic cancer. Within this learning center, you will have access to complimentary continuing medical education (CME) activities highlighting up-to-the-minute emerging evidence that can be applied to everyday practice. Additional resources include open access to the full text of relevant peer-reviewed articles, clinical guidelines, interactive infographics, and other materials dedicated to helping you improve patient care.

As new data emerge, we will be updating the Progress in Pancreatic Cancer Learning Center with new CME activities and timely materials, so please check back often for the latest offerings.

We know you will find these resources helpful in your clinical practice, and hope that you will make the Progress in Pancreatic Cancer Learning Center your destination for pancreatic cancer education.

Take Course »

Credits: 0.75 AMA PRA Category 1 Credit™ per module
Bladder Cancer banner 116x140

Management of Patients with Bladder Cancer, Elsevier CME Independent Conference Highlights of the ASCO-GU Genitourinary Cancer Symposiums 2018*

Format: Webcast

This conference reporter webcast on bladder cancer is based on a roundtable discussion by three experts. During the webcast they provide an overview of challenges in the management of bladder cancer and summarize and discuss recent data presented during the ASCO-GU 2018 Symposium. The experts examine clinical trial outcomes of immunotherapies for bladder cancer and address the question of how current, novel, and emerging treatment options (when approved) could be implemented in individualized treatment plans to optimize treatment selection and outcomes for patients with bladder cancer.

*This webcast is not endorsed by the conference organizer. The Elsevier Office of Continuing Medical Education is an independent medical education company that provides clinical updates, analysis, and expert perspectives through conference-coverage educational programs.

Take Course »

Credits: 1.0 AMA PRA Category 1 Credit™
Colorectal Cancer banner 116x140

Management of Patients with Colorectal Cancer, Elsevier CME Independent Conference Highlights of the ASCO-GI 2018 Annual Meeting*

Format: Webcast

*This webcast is not endorsed by the conference organizer. The Elsevier Office of Continuing Medical Education is an independent medical education company that provides clinical updates, analysis, and expert perspectives through conference-coverage educational programs.

This conference reporter webcast on colorectal cancer is based on a roundtable discussion by three experts. During the webcast they provide an overview of challenges in the management of colorectal cancer and summarize and discuss recent data presented during the ASCO-GI 2018 Symposium. The experts examine clinical trial outcomes of targeted therapies for colorectal cancer and address the question of how current, novel, and emerging treatment options (when approved) could be implemented in individualized treatment plans to optimize treatment selection and outcomes for patients with colorectal cancer.

Credits: 1.0 AMA PRA Category 1 Credit™
ASH 2017 IMMUNO banner 116x140 thumbnail

Immunotherapy in Hematological Malignancies

Format: Webcast

This is a CME-accredited Elsevier Conference Reporter webcast based on a virtual roundtable discussion on immunotherapy in hematological malignancies. During the discussion three key opinion leaders summarize and give their expert opinion on important data from abstracts presented at the American Society of Hematology (ASH) 2017 Annual Meeting. The webcast lasts approximately 1 hour.

*This webcast is not endorsed by the conference organizer. Elsevier Office of Continuing Medical Education is an independent medical education company that provides clinical updates, analysis, and expert perspectives through conference coverage educational programs.

Take Course »

Credits: 1.00 AMA PRA Category 1 Credit(s)™
ASH 2017 Update MM banner 116x140

Management of Patients With Relapsed and/or Refractory Multiple Myeloma

Format: Webcast

This is a CME-accredited Elsevier Conference Reporter webcast based on a virtual roundtable discussion on the management of patients with relapsed and/or refractory multiple myeloma. During the virtual roundtable discussion, 3 experts summarize and give their expert opinion on important data from abstracts presented at the American Society of Hematology Association (ASH) 2017 Annual Meeting.

*This webcast is not endorsed by the conference organizer. Elsevier Office of Continuing Medical Education is an independent medical education company that provides clinical updates, analysis, and expert perspectives through conference-coverage educational programs.

Take Course »

Credits: 1.00 AMA PRA Category 1 Credit(s)™